Parametric or nonnormally distributed values. SPSS partial correlation analysis was performed to calculate multivariate correlations of OCT- and VEP parameters, adjusting for age, sex, laboratory parameters and clinical disease score. Subjects with missing data were excluded from the respective analysis. The means and standard deviations are reported in the results section.ResultsThe patients and controls did not differ significantly in age or sex. The OCT findings, laboratory parameters and clinical data are shown in table 1.Routine OCT Parameters, RNFL Thickness and Macular ThicknessThe peripapillary RNFL thickness, paramacular thickness and the thickness of the different retinal layers were measured as illustrated in figure 1A. The patients’ retinal parameters are shown in table 1. The mean peripapillary RNFL was significantly thinner compared to age and sex matched controls (Means 6 standard deviation (M6SD): Wilson’s disease 95.368.8 mm vs. controls 99.6610.4 mm, figure 1 A) as was the mean total macular thickness (M6SD: Wilson’s disease 311.2615.79 mm vs. controls 321.0614.8 mm, figure 1 B). The reduction of the macular thickness was most pronounced in the inferior Title Loaded From File quadrant and this was the only quadrant that was significantly reduced in Wilson’s disease patients compared with controls. The RNFL of our Wilson’s disease patients was more homogenously reduced and none of the quadrants alone was significantly reduced.OCT Manual SegmentationDue to the high resolution of the latest generation spectraldomain OCT device used in this study, we were capable of identifying the different retinal layers in transfoveal scans. We manually segmented the retinal layers in Title Loaded From File horizontal scans through the middle of the fovea and measured the thickness of the different layers (figure 2 A) as previously described [18,30]. The results are summarized in table 1. The retinal ganglion cell- and inner plexiform layer complex (GCIP) and the inner nuclear layer (INL) were reduced in Wilson’s disease patients (M6SD: GCIP: 95.560.8 mm, INL: 38.963.6 mm) compared with controls (M6SD: GCIP: 99.860.8 mm, INL: 44.160.5 mm) (figure 2B ). We observed no significant differences in the thickness of the mean outer plexiform layer (M6SD: OPL: controls 33.960.8 mm, Wilson’s disease 36.260.7 mm) or the outer nuclear layer (M6SD: ONL: controls: 10661.3 mm, Wilson’s disease: 10661.4 mm) (figure 2D ).Figure 2. Manual segmentation: the thickness of GCIP and INL is reduced in Wilson’s disease. A The different retinal layers were manually segmented in single horizontal foveal scans and the images 1407003 are displayed as negatives to better differentiate the different layers. The thickness of the different layers was measured at the vertical lines indicating the thickest point, both nasally and temporally of the fovea, except for the ONL, which was measured centrally along the vertical line. B Scatter plots of the mean thickness of the different retinal layers. Each point represents the mean of the two eyes of one patient. The mean of all patients is indicated by a horizontal bar. Significant differences are indicated by asterisks (p,0.05, two-tailed t test); nonsignificant differences are indicated as n.s. doi:10.1371/journal.pone.0049825.gStatistical EvaluationStatistical analyses were performed using Microsoft Excel and Prism 5.0 (GraphPad) and SPSS Statistics 20 (IBM). To compare Wilson’s disease patients with controls, a two-tailed t-test was used and both eyes of each subject were.Parametric or nonnormally distributed values. SPSS partial correlation analysis was performed to calculate multivariate correlations of OCT- and VEP parameters, adjusting for age, sex, laboratory parameters and clinical disease score. Subjects with missing data were excluded from the respective analysis. The means and standard deviations are reported in the results section.ResultsThe patients and controls did not differ significantly in age or sex. The OCT findings, laboratory parameters and clinical data are shown in table 1.Routine OCT Parameters, RNFL Thickness and Macular ThicknessThe peripapillary RNFL thickness, paramacular thickness and the thickness of the different retinal layers were measured as illustrated in figure 1A. The patients’ retinal parameters are shown in table 1. The mean peripapillary RNFL was significantly thinner compared to age and sex matched controls (Means 6 standard deviation (M6SD): Wilson’s disease 95.368.8 mm vs. controls 99.6610.4 mm, figure 1 A) as was the mean total macular thickness (M6SD: Wilson’s disease 311.2615.79 mm vs. controls 321.0614.8 mm, figure 1 B). The reduction of the macular thickness was most pronounced in the inferior quadrant and this was the only quadrant that was significantly reduced in Wilson’s disease patients compared with controls. The RNFL of our Wilson’s disease patients was more homogenously reduced and none of the quadrants alone was significantly reduced.OCT Manual SegmentationDue to the high resolution of the latest generation spectraldomain OCT device used in this study, we were capable of identifying the different retinal layers in transfoveal scans. We manually segmented the retinal layers in horizontal scans through the middle of the fovea and measured the thickness of the different layers (figure 2 A) as previously described [18,30]. The results are summarized in table 1. The retinal ganglion cell- and inner plexiform layer complex (GCIP) and the inner nuclear layer (INL) were reduced in Wilson’s disease patients (M6SD: GCIP: 95.560.8 mm, INL: 38.963.6 mm) compared with controls (M6SD: GCIP: 99.860.8 mm, INL: 44.160.5 mm) (figure 2B ). We observed no significant differences in the thickness of the mean outer plexiform layer (M6SD: OPL: controls 33.960.8 mm, Wilson’s disease 36.260.7 mm) or the outer nuclear layer (M6SD: ONL: controls: 10661.3 mm, Wilson’s disease: 10661.4 mm) (figure 2D ).Figure 2. Manual segmentation: the thickness of GCIP and INL is reduced in Wilson’s disease. A The different retinal layers were manually segmented in single horizontal foveal scans and the images 1407003 are displayed as negatives to better differentiate the different layers. The thickness of the different layers was measured at the vertical lines indicating the thickest point, both nasally and temporally of the fovea, except for the ONL, which was measured centrally along the vertical line. B Scatter plots of the mean thickness of the different retinal layers. Each point represents the mean of the two eyes of one patient. The mean of all patients is indicated by a horizontal bar. Significant differences are indicated by asterisks (p,0.05, two-tailed t test); nonsignificant differences are indicated as n.s. doi:10.1371/journal.pone.0049825.gStatistical EvaluationStatistical analyses were performed using Microsoft Excel and Prism 5.0 (GraphPad) and SPSS Statistics 20 (IBM). To compare Wilson’s disease patients with controls, a two-tailed t-test was used and both eyes of each subject were.
Related Posts
Cinnamtannin B-1
Product Name : Cinnamtannin B-1Description:Cinnamtannin B-1 is a proanthocyanidin with multiple biological functions, including antioxidant effects. Cinnamtannin B-1 inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced osteoporosis in vivo. Cinnamtannin B-1 can be used for the research osteoporosis and colon cancers.CAS: 88082-60-4Molecular Weight:864.76Formula: C45H36O18Chemical Name: (1R,5R,6R,7S,13S,21R)-5,13-bis(3,4-dihydroxyphenyl)-7-[(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-1-benzopyran-8-yl]-4,12,14-trioxapentacyclo[11.7.1.0²,¹¹.0³,⁸.0¹⁵,²⁰]henicosa-2,8,10,15,17,19-hexaene-6,9,17,19,21-pentolSmiles : OC1C=C2O[C@]3(OC4=CC(O)=C5[C@@H]([C@@H](O)[C@H](OC5=C4[C@H]([C@H]3O)C2=C(O)C=1)C1=CC(O)=C(O)C=C1)C1C2O[C@@H]([C@H](O)CC=2C(O)=CC=1O)C1=CC(O)=C(O)C=C1)C1=CC(O)=C(O)C=C1InChiKey: BYSRPHRKESMCPO-LQNPQWRQSA-NInChi : InChI=1S/C45H36O18/c46-18-10-27(54)33-31(11-18)62-45(17-3-6-22(49)26(53)9-17)44(59)38(33)36-32(63-45)14-29(56)35-37(39(58)41(61-43(35)36)16-2-5-21(48)25(52)8-16)34-28(55)13-23(50)19-12-30(57)40(60-42(19)34)15-1-4-20(47)24(51)7-15/h1-11,13-14,30,37-41,44,46-59H,12H2/t30-,37+,38-,39-,40-,41-,44-,45+/m1/s1Purity: ≥98% (or refer to the Certificate […]
Proteasome 19S Rpn12/S14 subunit (human) polyclonal antibody
Product Name : Proteasome 19S Rpn12/S14 subunit (human) polyclonal antibodySequence: Purity: Molecular Weight:Solubility : Appearance: Use/Stability : Description: CAS : Solubility: Formula: Additional Information : | Alternative Name 26S proteasome non-ATPase regulatory subunit 8 | Application IHC, WB | Formulation Liquid.{{112-80-1} MedChemExpress|{112-80-1} Protocol|{112-80-1} References|{112-80-1} custom synthesis} In PBS containing 10mM sodium azide.{{2390147-17-6} web|{2390147-17-6} Protocol|{2390147-17-6} Purity|{2390147-17-6} […]
View.RNA extraction from brain sections and RT-PCR/PCRThe brain slices had been lysed, and total RNA
View.RNA extraction from brain sections and RT-PCR/PCRThe brain slices had been lysed, and total RNA was extracted utilizing the RNeasy Lipid Tissue kit (Qiagen) in accordance with the manufacturer’s guidelines and adjusted to 1 g/mL. RNA have been retro-transcripted employing the `High-capacity’ cDNA reverse transcription kit (Applied Biosystems); cDNA was generated after reverse transcription of […]